Imatinib shows increased survival in ICR ’s Phase III oncology trial

A Phase III clinical trial of imatinib (Glivec) conducted by UK researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust demonstrated increased survival in patients with advanced gastrointestinal stromal tumo …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news